Made in Maryland: End-to-End Biotech Innovation Showcase
Overview
Made in Maryland at MacroGenics showcases a company at the forefront of Maryland’s antibody engineering and cancer therapy development—setting the stage for a broader look at the strength and breadth of the state’s biotech community.
The program brings together people from across research, development, and manufacturing to show how the full drug development process can—and often does—happen entirely within the state. Through conversations, hands-on experiences, and examples of local innovation, the event highlights the partnerships and capabilities that make Maryland a standout place to discover, develop, and deliver new therapies.
Agenda
4:30pm Check-In + Networking
5:00pm Welcome + Opening Remarks
Tom Spitznagel, Senior Vice President, Technical Operations
Matt Johnson, Contract Manufacturing Manager, MacroGenics
5:10pm Lightning Talks
TEDCO (invited)
Millipore (BioReliance) | Pedro Diaz, Global Head, Biosafety Testing Operations and US site head
Quality Biological | Valerie Fremont, CSO/VP Market Development & Strategy, Quality Biological, Inc.
Bora Pharmaceuticals (invited)
CRB | Michael Konstantopoulos, Director, Maryland Design Leader
5:55pm Networking
About the Lightning Talks
Lightning Talk 1: Where Biotech Begins – Funding Discovery into Companies (TEDCO)
Every drug development journey starts with an idea that needs backing. TEDCO represents the earliest step in Maryland’s biotech pipeline, where research is funded, companies are formed, and scientific potential is transformed into investable, buildable ventures. This is where innovation gets its first real chance to move forward.
Lightning Talk 2: Building Reliable Biology – From Experiment to Process (Quality Biological)
Breakthrough science only matters if it can be repeated and scaled. Quality Biological shows how high-quality cell culture products underpin the transition from discovery to development, providing the materials and consistency needed to turn early experiments into viable therapeutic programs.
Lightning Talk 3: De-Risking Development – Testing for What Comes Next (MilliporeSigma BioReliance)
Before a therapy can move into manufacturing or the clinic, it must be proven safe, compliant, and ready. MilliporeSigma BioReliance demonstrates how biosafety testing and analytical services reduce risk, support regulatory confidence, and prepare programs for the next phase of development.
Lightning Talk 4: Making Therapies Patient-Ready – Fill-Finish in Maryland (Bora Pharmaceuticals)
Drug development doesn’t end at manufacturing. Bora Pharmaceuticals highlights how fill-finish and packaging complete the journey, transforming drug substance into final, patient-ready product—entirely within the regional ecosystem.
Lightning Talk 5: Building the Places Where Biotech Happens (CRB)
None of this is possible without the right infrastructure. CRB closes the story by showing how purpose-built labs and manufacturing facilities enable every step of drug development, ensuring Maryland can support innovation from startup to scale.
Host
MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The company advances its pipeline using a proprietary suite of next-generation antibody-based technology platforms with applicability across multiple therapeutic areas.
MacroGenics’ platforms and deep protein engineering expertise have enabled the development of promising product candidates and supported several strategic collaborations with global pharmaceutical and biotechnology partners.
Learn more at macrogenics.com and FOLLOW them on LinkedIn.